Mark Lingen

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. pmc Validation of LOH profiles for assessing oral cancer risk
    Mark W Lingen
    Department of Pathology, The University of Chicago, 5841 South Maryland Ave, MC 6101, Chicago, IL 60637, USA
    Cancer Prev Res (Phila) 5:1075-7. 2012
  2. pmc Identification and functional analysis of NOL7 nuclear and nucleolar localization signals
    Guolin Zhou
    Department of Pathology, The University of Chicago, Chicago, IL, USA
    BMC Cell Biol 11:74. 2010
  3. doi request reprint Brush-based cytology screening in the tonsils and cervix: there is a difference!
    Mark W Lingen
    Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
    Cancer Prev Res (Phila) 4:1350-2. 2011
  4. doi request reprint Screening for oral premalignancy and cancer: what platform and which biomarkers?
    Mark W Lingen
    Department of Pathology, The University of Chicago, 5841 South Maryland Avenue, MC 6101, Chicago, IL 60637, USA
    Cancer Prev Res (Phila) 3:1056-9. 2010
  5. pmc Critical evaluation of diagnostic aids for the detection of oral cancer
    Mark W Lingen
    Department of Pathology, The University of Chicago, Pritzker School of Medicine, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Oral Oncol 44:10-22. 2008
  6. ncbi request reprint Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression
    Rifat Hasina
    Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
    Cancer Res 63:555-9. 2003
  7. pmc ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis
    Rifat Hasina
    Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
    Cancer Prev Res (Phila) 2:385-93. 2009
  8. ncbi request reprint Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase
    Ezra Eddy Wyssam Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cancer Res 66:6296-303. 2006
  9. pmc The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma
    Tanguy Y Seiwert
    Section of Hematology Oncology, Department of Medicine and University of Chicago Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
    Cancer Res 69:3021-31. 2009
  10. pmc A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cancer Res 69:65-74. 2009

Research Grants

  1. ORAL CANCER, RETINOIDS, AND ANTIANGIOGENESIS
    Mark Lingen; Fiscal Year: 2002
  2. Molecular Profiling of Premalignant Oral Lesions
    Mark Lingen; Fiscal Year: 2007
  3. MOLECULAR DETERMINANTS OF ANGIOGENSIS IN ORAL CANCER
    Mark Lingen; Fiscal Year: 2005
  4. Automated Tissue Arrayer
    Mark Lingen; Fiscal Year: 2004
  5. Oral Cancer, Chemoprevention, and Anti-Angiogenesis
    Mark Lingen; Fiscal Year: 2009

Collaborators

Detail Information

Publications18

  1. pmc Validation of LOH profiles for assessing oral cancer risk
    Mark W Lingen
    Department of Pathology, The University of Chicago, 5841 South Maryland Ave, MC 6101, Chicago, IL 60637, USA
    Cancer Prev Res (Phila) 5:1075-7. 2012
    ..The perspective also discusses some of the challenges and opportunities of incorporating predictive biomarkers into monitoring and refined enrollment criteria for prevention studies...
  2. pmc Identification and functional analysis of NOL7 nuclear and nucleolar localization signals
    Guolin Zhou
    Department of Pathology, The University of Chicago, Chicago, IL, USA
    BMC Cell Biol 11:74. 2010
    ..Further, NOL7 was observed to localize to the nucleus and nucleolus of cells. However, the mechanisms regulating its subcellular localization have not been elucidated...
  3. doi request reprint Brush-based cytology screening in the tonsils and cervix: there is a difference!
    Mark W Lingen
    Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
    Cancer Prev Res (Phila) 4:1350-2. 2011
    ....
  4. doi request reprint Screening for oral premalignancy and cancer: what platform and which biomarkers?
    Mark W Lingen
    Department of Pathology, The University of Chicago, 5841 South Maryland Avenue, MC 6101, Chicago, IL 60637, USA
    Cancer Prev Res (Phila) 3:1056-9. 2010
    ..This perspective also discusses some of the challenges and current limitations of developing biomarkers to screen not only for oral premalignancy and early cancer but for human papillomavirus-related oropharyngeal neoplasia as well...
  5. pmc Critical evaluation of diagnostic aids for the detection of oral cancer
    Mark W Lingen
    Department of Pathology, The University of Chicago, Pritzker School of Medicine, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Oral Oncol 44:10-22. 2008
    ....
  6. ncbi request reprint Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression
    Rifat Hasina
    Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
    Cancer Res 63:555-9. 2003
    ..These data demonstrate that genomic profiling can then be used to identify potential genotypic/phenotypic biomarkers that may predict which dysplastic lesions are most likely to progress to HNSCC...
  7. pmc ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis
    Rifat Hasina
    Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
    Cancer Prev Res (Phila) 2:385-93. 2009
    ..In addition, these data support the hypothesis that inhibitors of angiogenesis may be promising chemopreventive agents...
  8. ncbi request reprint Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase
    Ezra Eddy Wyssam Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cancer Res 66:6296-303. 2006
    ....
  9. pmc The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma
    Tanguy Y Seiwert
    Section of Hematology Oncology, Department of Medicine and University of Chicago Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
    Cancer Res 69:3021-31. 2009
    ..MET inhibition abrogated MET functions, including proliferation, migration/motility, and angiogenesis. MET is a promising, novel target for HNSCC and combination approaches with cisplatin or EGFR inhibitors should be explored...
  10. pmc A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cancer Res 69:65-74. 2009
    ....
  11. pmc Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications
    Rifat Hasina
    Department of Pathology, Medicine and Radiation and Cellular Oncology, The University of Chicago, Chicago, IL, USA
    Lab Invest 88:342-53. 2008
    ..Finally, they suggest that studies in conjunction with the ongoing clinical trials that explore the correlation between target expression and clinical outcome are warranted...
  12. ncbi request reprint Head and neck cancer: the pursuit of molecular diagnostic markers
    Rifat Hasina
    Department of Pathology, The University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Semin Oncol 31:718-25. 2004
    ....
  13. ncbi request reprint The expanding role of systemic therapy in head and neck cancer
    Ezra E W Cohen
    Department of Medicine, Section of Hematology Oncology, University of Chicago Cancer Research Center, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637 1470, USA
    J Clin Oncol 22:1743-52. 2004
    ..This review will focus on current therapy for locally advanced, recurrent, and metastatic SCCHN and discuss controversies and directions for future research...
  14. ncbi request reprint Retinoic acid modulates the ability of macrophages to participate in the induction of the angiogenic phenotype in head and neck squamous cell carcinoma
    Cory Liss
    Department of Pathology, The Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL 60153, USA
    Int J Cancer 100:283-9. 2002
    ..In addition, it underscores the necessity to develop antiangiogenic treatment protocols that can block each of the ways in which new blood vessel growth is induced in tumor microenvironments...
  15. ncbi request reprint Oral cancer screening aids: where is the science?
    Mark W Lingen
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103:153-4. 2007
  16. doi request reprint The changing face of head and neck cancer
    Mark W Lingen
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106:315-6. 2008
  17. ncbi request reprint Improving translational research for oral cancer screening aids: putting my "money" where my mouth is
    Mark W Lingen
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104:301-2. 2007
  18. ncbi request reprint Classification and identification of genes associated with oral cancer based on gene expression profiles. A preliminary study
    Winston Patrick Kuo
    N Y State Dent J 69:23-6. 2003
    ..We found 651 genes to be associated with cancer. This article describes a preliminary study of current developments from the Human Genome Project (HGP) and its application to OSCC...

Research Grants17

  1. ORAL CANCER, RETINOIDS, AND ANTIANGIOGENESIS
    Mark Lingen; Fiscal Year: 2002
    ....
  2. Molecular Profiling of Premalignant Oral Lesions
    Mark Lingen; Fiscal Year: 2007
    ..This molecular analysis may also greatly improve diagnostic prediction compared to the cellular pattern recognition currently used by pathologists. ..
  3. MOLECULAR DETERMINANTS OF ANGIOGENSIS IN ORAL CANCER
    Mark Lingen; Fiscal Year: 2005
    ....
  4. Automated Tissue Arrayer
    Mark Lingen; Fiscal Year: 2004
    ..An already established Internal Advisory Committee will oversee an equitable and appropriate use by a broad disciplinary group of scientists while giving priority to NIH-supported groups. ..
  5. Oral Cancer, Chemoprevention, and Anti-Angiogenesis
    Mark Lingen; Fiscal Year: 2009
    ..abstract_text> ..